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Abstract
We describe a device for assessing the effects of diffusible molecules on electrophysiological
recordings from multiple neurons. This device allows for the infusion of reagents through a cannula
located among an array of micro-electrodes. The device can easily be customized to target specific
neural structures. It is designed to be chronically implanted so that isolated neural units and local
field potentials are recorded over the course of several weeks or months. Multivariate statistical and
spectral analysis of electrophysiological signals acquired using this system could quantitatively
identify electrical “signatures” of therapeutically useful drugs.
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1. Introduction
For many decades, animal models have been used for the identification of drugs that ameliorate
psychiatric, neuropathological and neuro-degenerative disorders. The principle means of
assessing efficacy has been the measurement of behavioral responses. The development of
anti-depressant drugs is an excellent example of the successful application of this methodology
(Cryan et al. 2002). Similarly, the development of drugs for the treatment of epilepsy uses
behavioral assays of seizure activity (White 2002, 2003). However, behavioral assessment is
an indirect measurement of drug effects on neural circuitry. Recent data have shown that
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electrophysiological signals are modulated by anti-depressant drugs (Szabo and Blier 2001;
Szabo et al. 1999) and serve as a predictor of drug efficacy (Gallinat et al. 2000; Hegerl et al.
2001; Hegerl and Juckel 2000). In addition, the effects of infusing substances into the striatum
have been quantified using electrophysiology to understand their relationship to disorders such
as Parkinson’s disease and schizophrenia (Pierce and Rebec 1995; Stanford et al. 2005, In
Press). These results suggest that systematic and quantitative electrophysiological screening
of pharmaceuticals may prove to be a useful tool in drug development for a variety of
neurological and psychological pathologies.
More recently, due to the rapidly developing field of neural prosthetics and brain stimulation
a need has arisen to maintain chronic, i.e. several years, electrophysiological contact with
neurons in the brain. Currently available, chronically implanted micro-electrode arrays for
recording single neural units in neural prosthetic applications lose signals over time. In most
cases these micro-electrodes fail completely after being implanted in the brain for several
months to a few years. This loss of signal is thought to be primarily due to the inflammatory
response engendered by insertion of the electrodes into the brain and subsequent relative
motion of the electrodes and the brain (Polikov et al. 2005; Szarowski et al. 2003; Turner et
al. 1999). Even arrays that float with the brain suffer from inflammatory responses that could
be ameliorated by a pharmacological intervention (House et al. 2006; Kim et al. 2006; Vetter
et al. 2004; Warren et al. 2004).
The device described here offers a simple and effective way to approach both drug development
and electrode contact longevity issues. Although several cannula-eletrode devices have been
designed for use in both behaving rats (Laird et al. 1979; Rebec et al. 1993) and monkeys
(Kliem and Wichmann 2004), the device presented here possesses several significant
advantages. It its extremely light weight, simple to use, highly configurable, bio-compatible,
and can acquire both isolated neural units and local field potentials (LFPs), while delivering
drugs through a cannula.
2. Materials and Methods
2.1 Assembly of the cannula-multielectrode array
An apparatus for simultaneously measuring electrophysiological signals and for infusing
reagents in close proximity to the electrodes is described. The device is comprised of a body,
a cannula, and electrodes mounted on the body so that reagents supplied by the cannula are
delivered in proximity of the electrodes. The cannula and electrode can be arbitrarily configured
with respect to each other in order to allow the device to be customized for optimal implantation
in specific brain regions.
The device (Fig. 1) is based upon a commercially available cannula system (Brain Infusion kit
II, Alzet). The electrodes are made up first, as single long “hat pins”. Holes are drilled at the
desired location into one of the electrode mounting disks supplied with the Alzet kit. The rigid
hat pin electrode is placed through the pre-drilled hole with the desired length extending below
the electrode mounting disk and tacked in place using a small amount of biomedical grade
cyanoacrylate glue. The length of electrode above the electrode mounting disk is trimmed to
a shaft of approximately 1mm and stripped of insulation. A flexible 33 gauge insulated copper
wire lead is soldered to the electrode shaft so that it is at a right angle to the shaft and parallel
to the electrode mounting disk. The other end of the copper lead wire can then be attached to
any convenient electrical connector. The cannula is then slid into the central hole of the
electrode mounting disk, until the desired length of the cannula is protruding below the disk,
and tacked in place using the cyanoacrylate glue. The gap between the electrode mounting disk
and the base of the cannula assembly is filled with Loctite M-31CL Medical Device Epoxy to
protect wire leads and strengthen the device.
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The electrodes are manufactured from the biocompatible materials, platinum/iridium alloy and
Paralene-C insulation. The units tested utilize 75 micron diameter electrodes sharpened to 1 -
2 microns with impedance of ~0.3 megaohms. The electrodes and cannula extended 2.5mm
and 2.0mm below the electrode mounting disk. Electrode materials and construction can also
be customized according to the needs for insertion into different brain structures, e.g. longer
electrodes for recording from deep brain structures. The electrode manufacturing and device
assembly is carried out by Micro Probe Inc. (Gaithersburg, MD, USA).
Using the current version of the device, saline is infused using an osmotic mini-pump (Alzet).
This pump uses the force generated by an osmotic gradient to slowly infuse liquid over the
course of several days-to-weeks with no intervention.
2.2 Surgical implantation
The surgical implantation of the device is performed using a minimally invasive procedure.
An extended borehole procedure is performed. The device is then stereotaxically implanted
through the craniotomy. The duramater is pierced by the cannula and electrodes, but is
otherwise left intact. The device is anchored to the skull using titanium bone screws (Osteomed,
Addison, TX) and an island of methyl methacrylate forming a small head cap. A pocket is
formed by blunt dissection of a subcutaneous space between the scapulae and the osmotic pump
is placed into this pocket and connected to the cannula-electrode device with plastic tubing.
The scalp is sutured around the head-cap, leaving the electrical connector exposed (Fig. 2). A
skilled operator can implant the device in approximately 20 minutes from the onset of
anesthesia.
It was reported that cyanoacrylate gel (loctite 454) is a more effective and easier means of
cannula-electrode fixation since it does not require the use of skull screws for anchoring (Criado
et al. 2003). This would greatly reduce the time required for implantation.
2.3 Data acquisition and analysis
Since astrocytes often form a barrier around chronically implanted electrodes, we use
immunohistochemical staining for the astrocyte marker, glial fibrillary acidic protein (GFAP)
(Jankowsky et al. 2000). Briefly, animals are given an anesthetic overdose and transcardially
perfused with 10% formalin. Brains are then removed and immediately frozen in pre-chilled
isopentane. After embedding in Cryo-M-Bed (Bright, Huntingdon, UK), 20 μm frozen sagittal
sections through the region where the cannula-electrode device was implanted are collected.
The sections are incubated overnight at 4°C with anti-GFAP antibody diluted 1:500 in blocking
solution, and then incubated with a secondary antibody conjugated to a fluorescence marker
for visualization.
Electrophysiological data can be acquired using standard amplification, filtering, and analog
to digital converting systems. We recorded isolated neural-units and LFP using two signal
paths and with different filters applied to each path. We used a Dam-80 isolation amplifier and
filter (World Precision Instruments) and a National Instruments DAQ card. Electrical signals
are amplified with a gain of 10k and filtered at either 100 – 10,000 Hertz for recording neural
units, or 0.1 – 10,000 Hertz to acquire LFPs. Alternatively, a single broadband neural signal
could be recorded and differentially digitally filtered offline.
3. Results
We successfully implanted this device into the frontal or parietal cortices of five rats, and
obtained both electrophysiological and histological data. Activated astrocytes are a key part of
the inflammatory response to neural injury, and increased GFAP staining is a reliable maker
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of this response (Eng et al. 2000; Polikov et al. 2005; Szarowski et al. 2003; Turner et al.
1999). Several weeks post-implantation, we sacrificed the rats and performed GFAP
immunohistochemistry. As expected, compared to the non-implanted hemisphere, the tissue
around the electrode exhibits increased GFAP immunostaining (Fig. 3). We also collected
electrophysiological data at two - five time points over many weeks post-implantation (Figs.
4 and 5). Even though an increase in the inflammatory response was detected by
imunohistochemistry, we are able to collect high quality electrophysiological data. As
calculated by spike peak-to-peak divided by the RMS of the whole recording, the signal to
noise ratio of the recordings displayed in Fig. 4 is 19:1 for rat 2 and 25:1 for rat 3. Both the
high frequency spike data and the spectral analysis of the LFP demonstrate electro-
physiological activity two weeks post-implantation.
4. Discussion
The cannula-electrode device described here allows recording of the electrical signal from
single neural units, and the more global LFP signal, at multiple sites. The recordings of
electrical activity are made while a reagent is infused in close proximity to the recording
electrodes. Similar devices used by others are capable of recording at only a single location
(Kliem and Wichmann 2004; Rebec et al. 1993), or only EEG signals (Laird et al. 1979). The
present device is highly configurable so that electrical recordings and reagent infusion can be
targeted to specific neural structures.
We recorded electrical activity from, and infused saline into, the cerebral cortex, which served
as a proof of concept for the functionality of the device. Further work is, however, needed to
determine the effects of specific reagents on neural activity using this device, as well as the
ability of this device to record from multiple structures, e.g. the basal ganglia and cerebral
cortex, simultaneously. In addition, since cytokines such as interleukin (IL)-1, -4, -8, -10 and
tumor necrosis factor–α (TNF–α) can enhance repair of injured tissue (Spera et al. 1998;
Tanuma et al. 1997; Wang et al. 2002; Wang and Shuaib 2002), it would be interesting to use
the described cannula-electrode device to determine if such anti-inflammatory agents can
prolong the useful lifespan of the electrode arrays.
Recent studies have shown that electrophysiological signals from isolated neurons are affected
by neuroactive drugs such as anti-depressants (Szabo and Blier 2001; Szabo et al. 1999), and
that evoked potential responses can serve as a marker of anti-depressant efficacy (Gallinat et
al. 2000; Hegerl et al. 2001; Hegerl and Juckel 2000; Linka et al. 2004; Linka et al. 2005).
Such results suggest that there are likely to be electrophysiological signatures for neuro-active
drugs effective against a variety of neuro-pathologies. Recordings of neural units and LFP may
allow for the detection of such signatures in localized neural structures. The effects of intra-
cerebral infusion of pharmaceutical agents could then be examined for their effects upon
electrophysiological signatures.
This device could also serve as a tool for determining pharmaceutical methods of improving
the longevity of chronically implanted electrodes used in neural prosthetic applications. When
coupled with telemetry for wireless transmission of the neural signals (Harrison et al. 2007;
Neihart and Harrison 2005), there is no need for a transcutaneous electrical connector, so the
skin can be sutured completely closed over the acrylic head-cap. In such a configuration the
device could provide continuous infusion of reagents and monitoring of signals in the freely
behaving animal without requiring a wired connection and a commutator.
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A schematic and picture of the cannula-electrode device are shown. The schematic shows a
side view of the entire device and a top view of the disk upon which the electrodes are mounted,
and the electrical connector. The picture displays the complete device next to a scale in
centimeters. A – coupling to osmotic pump, B – electrode, C – cannula, D – electrode mounting
disk, E – electrical connector.
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The left panel shows the insertion of the cannula-multielectrode device using a stereotaxic arm
after placement of the osmotic pump sub-cutaneously between the scapulae. The right panel
shows the completed procedure with the electrical connector embedded in the acrylic head-
cap. A – stereotaxic arm, B – Electrical Connector, C – Titanium Screws, D – Syringe Applying
Acrylic, E – Tube Connecting to Osmotic Pump, F – Cannula-multielectrode device.
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Immunohistological staining for GFAP shows (A) an increased inflammatory response at the
site of one of the electrodes in comparison with (B) the contralateral hemisphere were no
electrodes were placed. Animal was sacrificed at 30 days post device implantation.
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Electrophysiological data collected from the cannula-electrode device from two rats (band pass
filtered 300 – 10000 Hertz). The top panels show multiple spikes over the course of one second
for Rat 2 and ten seconds for Rat 3. The middle panels zoom in on the temporal scale to show
two single spike discharges. This data was collected at 12 days (Rat 3) and 7 months (Rat 2)
post array implantation.
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Spectral analysis of electrophysiological data collected from the cannula-electrode device from
one rat (wideband filtered 0.1 – 10000 Hertz). The LFP exhibits a peak in the power spectrum
in the beta and low gamma frequencies (10 – 50 Hertz) typical of recordings from the cerebral
cortex. The data was acquired 15 days post array implantation. Red lines are equal to one
standard error.
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